Connect Biopharma Holdings Limited
CNTB
$2.65
-$0.01-0.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | 19.90% | 0.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 161.51% |
| Total Operating Expenses | -- | -- | -- | -27.42% | -33.65% |
| Operating Income | -- | -- | -- | 65.49% | 65.48% |
| Income Before Tax | -- | -- | -- | 70.70% | 70.56% |
| Income Tax Expenses | -- | -- | -- | 65.42% | -22.71% |
| Earnings from Continuing Operations | -- | -- | -- | 70.44% | 70.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | 70.44% | 70.44% |
| EBIT | -- | -- | -- | 65.49% | 65.48% |
| EBITDA | -- | -- | -- | 66.10% | 66.01% |
| EPS Basic | -- | -- | -- | 70.54% | 70.48% |
| Normalized Basic EPS | -- | -- | -- | 75.25% | 73.96% |
| EPS Diluted | -- | -- | -- | 70.52% | 70.39% |
| Normalized Diluted EPS | -- | -- | -- | 75.01% | 73.76% |
| Average Basic Shares Outstanding | -- | -- | -- | 0.25% | 0.19% |
| Average Diluted Shares Outstanding | -- | -- | -- | 0.49% | 0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |